NCT01457495CompletedPhase 2
Study to Assess Immunogenicity and Reactogenicity of SB Biologicals' DTPa-HBV-IPV/Hib Vaccine Given as Three-dose Primary Vaccination Course Compared to DTPa-IPV/Hib and HBV Administered Concomitantly at Separate Sites
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- GlaxoSmithKline
- Enrollment
- 312
- Primary Endpoint
- Number of subjects with antibody titers equal to or greater than cut-off value.
Study Overview
Brief Summary
This study will assess the immunogenicity of GlaxoSmithKline (GSK) Biologicals' (formerly SmithKline Beecham Biologicals') DTPa-HBV-IPV/Hib (Infanrix hexa™) vaccine compared to the separate administration of DTPa-HBV-IPV (Infanrix™ penta) and Hib (Hiberix™) vaccines administered at 3 and 5 months of age.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Ages
- 12 Weeks to 16 Weeks (Child)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •A male or female between 12 and 16 weeks of age at the time of the first vaccination.
- •Free of obvious health problems as established by medical history and clinical examination before entering into the study.
- •Written informed consent obtained from the parents or guardians of the subject after they have been advised of the risks and benefits of the study in a language which they clearly understood, and before performance of any study procedure.
Exclusion Criteria
- •Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) during the study period or within 30 days preceding the first dose of study vaccine.
- •Administration of chronic immunosuppressants or immune-modifying drugs during the study period.
- •Administration of a vaccine not foreseen by the study protocol during the period starting from one month before each dose and ending one month after each dose.
- •Previous vaccination against diphtheria, tetanus, pertussis, hepatitis B, polio and/or Hib diseases.
- •History of/or intercurrent diphtheria, tetanus, pertussis, hepatitis B, polio and/or Hib disease.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.
- •History of allergic disease or reaction likely to be exacerbated by any component of the vaccine, including allergic reactions to neomycin and polymyxin B.
- •Major congenital defects or serious chronic illness.
- •Progressive neurological disorders.
- •Administration of immunoglobulins and/or any blood products since birth and during the study period.
- •Acute febrile illness at the time of planned vaccination.
Arms & Interventions
DTPa 1 Group
Experimental
Intervention: DTPa-HBV-IPV/Hib (Infanrix-hexa™) (Biological)
DTPa 2 Group
Active Comparator
Intervention: DTPa-IPV/Hib (Infanrix-IPV/Hib™) (Biological)
DTPa 2 Group
Active Comparator
Intervention: HBV (Engerix™-B) (Biological)
Outcomes
Primary Outcomes
Number of subjects with antibody titers equal to or greater than cut-off value.
Time Frame: One month after the 2nd dose of the primary vaccination course (month 3)
Secondary Outcomes
- Immunogenicity with respect to components of the study vaccines in terms of antibody titers(One month after the 2nd dose (Month 3), before and one month after the 3rd dose of the primary vaccination course (Months 8 and 9))
- Occurrence of unsolicited symptoms(Within 30 days after each vaccination, and overall)
- Occurrence of solicited local symptoms(Within 4 days after each vaccination and overall)
- Immunogenicity with respect to components of the study vaccines in terms of number of seropositive subjects(One month after the 2nd dose (Month 3), before and one month after the 3rd dose of the primary vaccination course (Months 8 and 9))
- Immunogenicity with respect to components of the study vaccines in terms of number of subjects with a vaccine response(One month after the 3rd dose of the primary vaccination course (Month 9))
- Occurrence of solicited general symptoms(Within 4 days after each vaccination and overall)
- Occurrence of serious AEs(Throughout the entire study (approximately 9 months per subject) up to and including 30 days post-vaccination)
Investigators
Similar Trials
Completed
Phase 3
Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered SeparatelyTetanusDiphtheriaPertussisHaemophilus Influenzae Type b (Hib)PoliomyelitisHepatitis BNCT01457508GlaxoSmithKline440
Completed
Phase 3
Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio VaccineHaemophilus Influenzae Type bTetanusDiphtheriaAcellular PertussisPoliomyelitisHepatitis BNCT01457560GlaxoSmithKline80
Completed
Phase 3
Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactivated Poliovirus Vaccine, to BoostrixTM and Inactivated Poliovirus Vaccine Administered Separately and With Revaxis®TetanusAcellular PertussisDiphtheriaNCT01277705GlaxoSmithKline806
Completed
Phase 3
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in ChildrenInfluenzaNCT01196988GlaxoSmithKline3,027
Completed
Phase 3
Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female SubjectsInfections, PapillomavirusNCT00996125GlaxoSmithKline750